Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Wafermine (Ketamine Sublingual Wafer) in Healthy Adults
NCT07691372Phase 1Completed
- Sponsor
- iX Biopharma
- Start
- Aug 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Wafermine, sponsored by iX Biopharma. Primary endpoints: Peak Plasma Concentration of Ketamine and Norketamine at 36 hours, Terminal Elimination Half-Life of Ketamine and Norketamine at 36 hours and 2 more. Started Aug 2026; status: completed.
02
Drugs
Wafermine
Beyond the preview
Go deeper on NCT07691372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691372.